Glyxambi

Glyxambi is an oral tablet that combines the active ingredients linagliptin and empagliflozin. It is marketed in the European Union for the treatment of type 2 diabetes mellitus. The product belongs to the DPP‑4 inhibitor and SGLT2 inhibitor drug classes, providing a dual mechanism that targets blood glucose regulation. Both components are absorbed orally and act on different physiological pathways to improve glycemic control without requiring dose titration.

Glyxambi is indicated for adults with type 2 diabetes mellitus when additional glycemic control is needed beyond diet, exercise, and monotherapy.

- As an adjunct to diet and exercise in patients inadequately controlled on metformin alone. - In combination with other oral antidiabetic agents when a single drug does not achieve target HbA1c. - For patients who may benefit from both DPP‑4 inhibition and SGLT2 inhibition to reduce fasting and post‑prandial glucose. - To support weight management as empagliflozin can promote modest urinary glucose loss.

The safety profile of Glyxambi reflects the combined actions of linagliptin and empagliflozin, with side effects ranging from mild to serious.

Common: - Upper respiratory tract infection symptoms (e.g., nasopharyngitis) - Headache - Nausea or abdominal discomfort - Increased frequency of urination

Serious: - Severe hypoglycemia, particularly with insulin or sulfonylureas - Acute kidney injury or worsening renal function - Ketoacidosis (euglycemic diabetic ketoacidosis) - Serious genital or urinary tract infections

Before prescribing Glyxambi, clinicians should evaluate patient-specific factors and monitor for conditions that may increase risk.

- Assess renal function; empagliflozin is less effective in severe renal impairment. - Use caution in patients with a history of urinary or genital infections. - Monitor for signs of ketoacidosis, especially if insulin dose is reduced. - Evaluate cardiovascular status, as empagliflozin has demonstrated cardiovascular benefits but may not be suitable for all patients. - Review concomitant use of insulin or sulfonylureas to avoid hypoglycemia. - Consider pregnancy and lactation status; safety data are limited.

Glyxambi may interact with other medicines that affect glucose metabolism, renal function, or blood pressure.

Avoid: - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that could lower linagliptin exposure. - Loop diuretics combined with high-dose empagliflozin may increase risk of dehydration.

Use with caution: - Insulin, sulfonylureas, or meglitinides – increased risk of hypoglycemia. - Diuretics or antihypertensives – possible additive blood pressure lowering. - NSAIDs or other nephrotoxic agents – may worsen renal function. - Medications that raise serum potassium (e.g., ACE inhibitors) – monitor electrolytes.